Search

Your search keyword '"Sacchi, S"' showing total 4 results
Start Over Author "Sacchi, S" Journal blood
4 results on '"Sacchi, S"'

1. Bone Marrow Evaluation According to the PVSG and WHO Criteria in 90 Essential Thrombocythemia (ET) Patients Treated with PEG Interferon alpha-2b. Preliminary Results.

Author

Gugliotta, Luigi, primary, Bulgarelli, S., primary, Asioli, S., primary, Tieghi, A., primary, Gardini, G., primary, Sabattini, E., primary, Franco, V., primary, Boveri, E., primary, Kvasnicka, H. M., primary, Vianelli, N., primary, Candoni, A., primary, Latagliata, R., primary, Passamonti, F., primary, Rupoli, S., primary, Martinelli, V., primary, Zaccaria, A., primary, Lauria, F., primary, De Biasi, E., primary, Sacchi, S., primary, Gobbi, M., primary, Tabilio, A., primary, Cacciola, E., primary, Cacciola, R., primary, Grossi, A., primary, Mazza, P., primary, Bonifazi, F., primary, Favini, P., primary, Mandelli, F., primary, Baccarani, M., primary, and Thiele, J., primary

Published
2005
Full Text
View/download PDF

2. PEG Intron Treatment in 90 Patients with Essential Thrombocythemia (ET) Final Report of a Phase II Study.

Author

Gugliotta, Luigi, primary, Bulgarelli, S., additional, Vianelli, N., additional, Russo, D., additional, Candoni, A., additional, Rupoli, S., additional, Latagliata, R., additional, Sacchi, S., additional, Martinelli, V., additional, De Biasi, E., additional, Bucalossi, A., additional, Mazzotta, S., additional, Tabilio, A., additional, Passamonti, F., additional, Grossi, A., additional, Cacciola, E., additional, Cacciola, R., additional, Pogliani, E., additional, Bonifazi, F., additional, Fanin, R., additional, Leoni, P., additional, Mandelli, F., additional, Zaccaria, A., additional, Lauria, F., additional, Lazzarino, M., additional, Gobbi, M., additional, Bosi, A., additional, Mazza, P., additional, Fincato, G., additional, Favini, P., additional, and Baccarani, M., additional

Published
2005
Full Text
View/download PDF

3. Bone Marrow Biopsy and Aspirate Evaluation in 90 Patients with Essential Thrombocythemia Treated with PEG Interferon alpha-2b. Preliminary Results.

Author

Gugliotta, L., primary, Bulgarelli, S., additional, Tieghi, A., additional, Asioli, S., additional, Gardini, G., additional, Vianelli, N., additional, Candoni, A., additional, Latagliata, R., additional, Rupoli, S., additional, Martinelli, V., additional, Zaccaria, A., additional, De Biasi, E., additional, Sacchi, S., additional, Lauria, F., additional, Miglino, M., additional, Passamonti, F., additional, Tabilio, A., additional, Cacciola, E., additional, Grossi, A., additional, Pisapia, G., additional, Favini, P., additional, and Baccarani, M., additional

Published
2004
Full Text
View/download PDF

4. Bone Marrow Biopsy and Aspirate Evaluation in 90 Patients with Essential Thrombocythemia Treated with PEG Interferon alpha-2b. Preliminary Results

Author

Alfonso Zaccaria, Francesco Passamonti, Simona Bulgarelli, E. De Biasi, Vincenzo Martinelli, Emma Cacciola, Antonio Tabilio, Anna Candoni, Alessia Tieghi, Alberto Grossi, P. Favini, Roberto Latagliata, Silvia Asioli, Stefano Sacchi, Michele Baccarani, Maurizio Miglino, Luigi Gugliotta, Nicola Vianelli, Serena Rupoli, G. Gardini, Francesco Lauria, G. Pisapia, Gugliotta, L., Bulgarelli, S., Tieghi, A., Asioli, S., Gardini, G., Vianelli, N., Candoni, A., Latagliata, R., Rupoli, S., Martinelli, Vincenzo, Zaccaria, A., DE BIASI, E., Sacchi, S., Lauria, F., Miglino, M., Passamonti, F., Tabilio, A., Cacciola, E., Grossi, A., Pisapia, G., Favini, P., and Baccarani, M.

Subjects
medicine.medical_specialty, medicine.diagnostic_test, Essential thrombocythemia, business.industry, Immunology, Cell Biology, Hematology, medicine.disease, Biochemistry, Gastroenterology, Granulopoiesis, Surgery, medicine.anatomical_structure, Tolerability, Fibrosis, Internal medicine, PEG ratio, Biopsy, medicine, Platelet, nd, Bone marrow, business
Abstract

Ninety patients with Essential Thrombocythemia (ET) where object of a phase II prospective multicentre study designed to evaluate efficacy, safety and tolerability of a two years treatment with PEG Interferon α-2b (PEG Intron, Schering Plough). The patients, 30 M and 60 F, 18–72 years old (median 45), observed in 16 Hematological Institutions of the Gruppo Italiano Malattie Mieloproliferative Croniche (GIMMC), received the ET diagnosis according to the PVSG criteria. At PEG Intron treatment start the patients showed: previous cytoreduction 97% (IFN α 31%), platelet count >1000 x 109/L 81%, splenomegaly 22%. At the end of the first year The PEG Intron starting dose of 25 μg/week resulted increased to a mean value of 55 μg/week and the Hematological Response (HR = Plts 45 years, platelet count >1000 x109/L, Hb 50 μg/week. In conclusion, the present study shows that in ET patients a two years PEG Intron treatment, able to induce and to maintain the Hematological Response in the majority of cases, is associated to a decrease of bone marrow cellularity, granulopoiesis, erytropoiesis, MK number, size and ploidy and, moreover, with an increase of MK dystrophy and of bone marrow fibrosis. These preliminary data on bone biopsy and aspirate will be object of a planned centralized reevaluation by a Panel of Pathologists and Clinicians.

Published
2004

Catalog

Books, media, physical & digital resources
See catalog results